-
Something wrong with this record ?
Enzymatically stable unsaturated hyaluronan-derived oligosaccharides with selective cytostatic properties
T. Klejch, R. Buffa, M. Šimek, K. Nešporová, A. Exnerová, J. Bednařík, M. Brandejsová, H. Vágnerová, F. Fiala, V. Velebný
Language English Country England, Great Britain
Document type Journal Article
- MeSH
- Hyaluronan Receptors metabolism MeSH
- HT29 Cells MeSH
- Cytostatic Agents * pharmacology chemistry chemical synthesis MeSH
- Fibroblasts drug effects MeSH
- Hyaluronoglucosaminidase * metabolism antagonists & inhibitors MeSH
- Hyaluronic Acid * chemistry pharmacology MeSH
- Humans MeSH
- Mice MeSH
- Oligosaccharides * chemistry pharmacology MeSH
- Cell Proliferation * drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Hyaluronan, a linear glycosaminoglycan comprising D-N-acetylglucosamine and D-glucuronic acid, is the main component of the extracellular matrix. Its influence on cell proliferation, migration, inflammation, signalling, and other functions, depends heavily on its molecular weight and chemical modification. Unsaturated HA oligosaccharides are available in defined length and purity. Their potential therapeutic utility can be further improved by chemical modification, e. g., reduction. No synthesis of such modified oligosaccharides, either stepwise or by hyaluronan cleavage, has been reported yet. Here we show a three-step synthesis (esterification, depolymerization and reduction) of unsaturated even numbered hyaluronan oligosaccharides with carboxylates and the reducing terminus reduced to an alcohol. Particular oligosaccharides were synthesised. The modified oligosaccharides are not cleaved by mammalian or bacterial hyaluronidase and do not affect the growth of mouse and human fibroblasts. Further, MTT and NRU viability tests showed that they inhibit the growth of human colon carcinoma cells HT-29 by 20-50 % in concentrations 500-1000 μg/mL. Interestingly, this effect takes place regardless of CD44 receptor expression and was not observed with unmodified HA oligosaccharides. These compounds could serve as enzymatically stable building blocks for biologically active substances.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24013326
- 003
- CZ-PrNML
- 005
- 20250318144427.0
- 007
- ta
- 008
- 240725e20240404enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.carbpol.2024.122129 $2 doi
- 035 __
- $a (PubMed)38670770
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Klejch, Tomáš $u Contipro a. s., Dolní Dobrouč 401, 56102, Czech Republic. Electronic address: Tomas.Klejch@contipro.com
- 245 10
- $a Enzymatically stable unsaturated hyaluronan-derived oligosaccharides with selective cytostatic properties / $c T. Klejch, R. Buffa, M. Šimek, K. Nešporová, A. Exnerová, J. Bednařík, M. Brandejsová, H. Vágnerová, F. Fiala, V. Velebný
- 520 9_
- $a Hyaluronan, a linear glycosaminoglycan comprising D-N-acetylglucosamine and D-glucuronic acid, is the main component of the extracellular matrix. Its influence on cell proliferation, migration, inflammation, signalling, and other functions, depends heavily on its molecular weight and chemical modification. Unsaturated HA oligosaccharides are available in defined length and purity. Their potential therapeutic utility can be further improved by chemical modification, e. g., reduction. No synthesis of such modified oligosaccharides, either stepwise or by hyaluronan cleavage, has been reported yet. Here we show a three-step synthesis (esterification, depolymerization and reduction) of unsaturated even numbered hyaluronan oligosaccharides with carboxylates and the reducing terminus reduced to an alcohol. Particular oligosaccharides were synthesised. The modified oligosaccharides are not cleaved by mammalian or bacterial hyaluronidase and do not affect the growth of mouse and human fibroblasts. Further, MTT and NRU viability tests showed that they inhibit the growth of human colon carcinoma cells HT-29 by 20-50 % in concentrations 500-1000 μg/mL. Interestingly, this effect takes place regardless of CD44 receptor expression and was not observed with unmodified HA oligosaccharides. These compounds could serve as enzymatically stable building blocks for biologically active substances.
- 650 12
- $a kyselina hyaluronová $x chemie $x farmakologie $7 D006820
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a oligosacharidy $x chemie $x farmakologie $7 D009844
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 12
- $a proliferace buněk $x účinky léků $7 D049109
- 650 12
- $a hyaluronoglukosaminidasa $x metabolismus $x antagonisté a inhibitory $7 D006821
- 650 12
- $a cytostatické látky $x farmakologie $x chemie $x chemická syntéza $7 D054697
- 650 _2
- $a buňky HT-29 $7 D019073
- 650 _2
- $a antigeny CD44 $x metabolismus $7 D018960
- 650 _2
- $a fibroblasty $x účinky léků $7 D005347
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Buffa, Radovan $u Contipro a. s., Dolní Dobrouč 401, 56102, Czech Republic $7 xx0330178
- 700 1_
- $a Šimek, Matěj $u Contipro a. s., Dolní Dobrouč 401, 56102, Czech Republic
- 700 1_
- $a Nešporová, Kristina $u Contipro a. s., Dolní Dobrouč 401, 56102, Czech Republic
- 700 1_
- $a Exnerová, Andrea $u Contipro a. s., Dolní Dobrouč 401, 56102, Czech Republic
- 700 1_
- $a Bednařík, Jiří $u Contipro a. s., Dolní Dobrouč 401, 56102, Czech Republic
- 700 1_
- $a Brandejsová, Martina $u Contipro a. s., Dolní Dobrouč 401, 56102, Czech Republic
- 700 1_
- $a Vágnerová, Hana $u Contipro a. s., Dolní Dobrouč 401, 56102, Czech Republic
- 700 1_
- $a Fiala, František $u Contipro a. s., Dolní Dobrouč 401, 56102, Czech Republic
- 700 1_
- $a Velebný, Vladimír $u Contipro a. s., Dolní Dobrouč 401, 56102, Czech Republic
- 773 0_
- $w MED00006149 $t Carbohydrate polymers $x 1879-1344 $g Roč. 336 (20240404), s. 122129
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38670770 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240725 $b ABA008
- 991 __
- $a 20250318144423 $b ABA008
- 999 __
- $a ok $b bmc $g 2143253 $s 1225192
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 336 $c - $d 122129 $e 20240404 $i 1879-1344 $m Carbohydrate polymers $n Carbohydr Polym $x MED00006149
- LZP __
- $a Pubmed-20240725